RetinAI and FVS Announce CE-MDR Certification for Co-developed AI-based Diabetic Retinopathy Screening Algorithm, LuxIA®
LuxIA is designed to screen adult diabetic patients for more-than-mild diabetic retinopathy (mtmDR). This indication for use provides critical support for ophthalmologists, general practitioners and trained healthcare professionals across the European Union to achieve an earlier diagnosis of mtmDR, a vision-threatening eye disease. This new certification demonstrates the strong collaboration between FVS and RetinAI, emphasizing both entities' commitment to deliver AI-driven tools that meet stringent regulatory standards and significantly enhance patient management and clinical outcomes.
The device is indicated for processing digital 45-degree colour fundus images from NW200, NW400 or equivalent Topcon cameras, ensuring seamless placement into existing clinical workflows. Together with RetinAI's existing portfolio of AI-based OCT analysis solutions, LuxIA complements a comprehensive suite of clinically validated, CE-certified AI modules focused on ophthalmology.
Dr. Carlos Ciller, CEO and co-founder of RetinAI, commented: 'Receiving CE-MDR certification for LuxIA underscores our shared commitment with FVS to advance leading-edge ophthalmic care to patients through reliable and impactful AI technology. This milestone is pivotal, enabling healthcare providers to improve patient management and outcomes for diabetic retinopathy across Europe, reinforcing our joint mission of transforming vision care through innovation.'
Dr. Juan Donate, MD, President of Fundación Ver Salud stated: 'We are excited about the newly received certification and look forward to the significant impact LuxIA will have in the European ophthalmology market. AI-driven screening solutions are critical to improving patient care, and we anticipate LuxIA will play a central role in achieving this.'
For further information or to request a demonstration of LuxIA and other ophthalmic solutions from FVS and RetinAI, please visit retinai.com.
For further information please contact:
At the company
Carlos Ciller, PhD, CEO - Ikerian AG and RetinAI Inc US [email protected], [email protected]
Media enquiries
Sue Charles, Charles Consultants - [email protected] +44 (0)7968726585
About Ikerian AG www.ikerian.com and RetinAI Inc. US www.retinai.com
Established in 2017, Ikerian AG (formerly RetinAI Medical AG) and its subsidiary, RetinAI U.S. Inc. ('Ikerian', 'RetinAI' and, together, 'the company'), develops software solutions to accelerate clinical, research and pharmaceutical workflows globally using advanced machine learning and computer vision, across ophthalmology, neurodegenerative disorders, vascular conditions, and rare diseases.
RetinAI builds tools to collect, organize and analyze health data from the eyes, enabling healthcare professionals to make the right decisions sooner in healthcare. RetinAI's international team leverages its clinical, technical, and scientific expertise to foster the transition from reactive to preventive medicine for severe eye diseases.
Follow us on LinkedInand
About FVS www.fundacionversalud.es/
FVS is a non-profit organization focused on training, research, and medical innovation, particularly in the field of ophthalmology. Its mission is to develop solutions that promote better clinical outcomes and enhance the quality of patient care.
Follow us on LinkedIn https://www.linkedin.com/in/fundaci%C3%B3n-ver-salud-983a621b3/ and X https://x.com/fversalud
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 minutes ago
- Business Wire
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27 th Annual Global Investment Conference in New York City, September 8-10, 2025
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- RenovoRx, Inc. ('RenovoRx' or the 'Company') (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ®, a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, will present at the H.C. Wainwright 27 th Annual Global Investment Conference. The conference will be held at the Lotte New York Palace Hotel in New York City, September 8-10, 2025. Mr. Bagai will be conducting a virtual presentation, which will be available for the duration of the conference, and afterwards on the Company's IR website at Mr. Bagai will discuss RenovoRx's ongoing commercialization efforts and the organic revenue growth reflecting the strong clinical need and market demand for RenovoCath as a standalone targeted drug-delivery product among both new and existing customers. Mr. Bagai's presentation will also highlight the latest developments in RenovoRx's ongoing Phase III TIGeR-PaC clinical trial, including the Data Monitoring Committee's (DMC) recent recommendation to continue the trial following its review of the second pre-planned interim analysis which was triggered by the 52 nd death. The TIGeR-PaC trial is evaluating RenovoRx's novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) for the treatment of locally advanced pancreatic cancer (LAPC). Presentation Details: To schedule a one-on-one investor meeting with Mr. Bagai, please contact KCSA Strategic Communications at RenovoRx@ About RenovoCath Based on its FDA clearance, RenovoCath ® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use ('IFU'), please see: About RenovoRx, Inc. RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ®, a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx's patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy. RenovoRx's novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating its novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA's 21 CFR 312 pathway. IAG utilizes RenovoCath, the Company's patented, FDA-cleared drug-delivery device, indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. The combination product candidate, which is enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides seven years of market exclusivity upon new drug application approval by the FDA. RenovoRx is also actively commercializing its TAMP technology and FDA-cleared RenovoCath as a stand-alone device. In December 2024, RenovoRx announced the receipt of its first commercial purchase orders for RenovoCath devices. Additionally, several of these customers have already initiated repeat orders in parallel to RenovoRx expanding the number of medical institutions initiating new RenovoCath orders, including several esteemed, high-volume National Cancer Institute-designated centers. To meet and satisfy the anticipated demand, RenovoRx will continue to actively explore further revenue-generating activity, either on its own or in tandem with a medical device commercial partner. For more information, visit Follow RenovoRx on Facebook, LinkedIn, and X. Cautionary Note Regarding Forward-Looking Statements This press release and statements of the Company's management made in connection therewith and at the investor conference described herein contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our clinical trials and studies, including anticipated timing, statements regarding the potential of RenovoCath ® or TAMP™ or regarding our ongoing TIGeR-PaC Phase III clinical trial study in LAPC, (ii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases and (iii) our efforts to explore commercialization strategies utilizing our TAMP technology. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections and statements relating to our research and development plans, intellectual property development, clinical trials, our therapy platform, business plans, financing plans, objectives and expected operating results, which are based on current expectations and assumptions that are subject to known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as 'may,' 'expects,' 'plans,' 'aims,' 'anticipates,' 'believes,' 'forecasts,' 'estimates,' 'intends,' and 'potential,' or the negative of these terms or other comparable terminology regarding RenovoRx's expectations strategy, plans or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: (i) the risk that our exploration of commercial opportunities for our TAMP technology may not lead to viable, revenue generating operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding, (iii) the timing of the initiation, progress and potential results (including the results of interim analyses) of our preclinical studies, clinical trials and our research programs; (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate, (v) that the applicable regulatory authorities may disagree with our interpretation of the data; research and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the implementation of our strategic plans for our business and product candidates; (xviii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates and research programs; (xix) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xx) the pricing, coverage and reimbursement of our product candidates, if approved; and (xxi) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled 'Risk Factors' in documents that we file from time to time with the Securities and Exchange Commission. Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.
Business Wire
34 minutes ago
- Business Wire
Fueling Success: CDPHP® and Delta Dental Insurance Company Make Children's Oral Health a Back-to-School Priority
ALBANY, N.Y.--(BUSINESS WIRE)--With kids across New York returning to school, CDPHP® and Delta Dental Insurance Company are reminding families that one of the most important school supplies doesn't go in a backpack—a healthy smile. CDPHP® and Delta Dental Insurance Company are reminding families to prioritize their children's oral health. According to the Centers for Disease Control and Prevention, tooth decay is the most common chronic disease among children in the United States. Share To raise awareness about the importance of preventive dental care, CDPHP®, in partnership with Delta Dental Insurance Company and the All Smiles Welcome campaign, is launching its Back-Tooth-School (BTS) initiative. This statewide promotion is designed to help CDPHP® members understand their no-cost dental benefits through Delta Dental Insurance Company and connect them with dentists to support lifelong oral health. The campaign emphasizes how prioritizing dental checkups is an essential step in ensuring children have the confidence and health to learn, grow, and succeed. Why Is This Important? Unaddressed dental pain and infections can hinder a child's ability to eat, sleep, and speak properly, which directly impacts their concentration and performance in the classroom. This is a widespread issue: according to the Centers for Disease Control and Prevention (CDC), tooth decay is the most common chronic disease among children in the United States. More than half of children ages 6-8 have had a cavity in at least one of their baby teeth and more than half of teens ages 12-19 have had a cavity in at least one of their permanent teeth. The good news? Cavities are preventable. With CDPHP®, dental checkups and preventive services, including fluoride treatments and molar sealants, are covered at no additional cost for children when they visit an in-network Delta Dental provider. These services are essential to protecting long-term oral health and preventing more serious issues later on. Bringing Oral Health to Local Families To help make dental health a family priority, the All Smiles Welcome and CDPHP® teams will be on the ground at two events, providing resources to support children's oral health and overall school readiness: August 23: New Jerusalem Community Block Party, Albany, NY September 6: Back-to-School Celebration at Watervliet High School, Watervliet, NY Care Managers will be on-site at both events to provide free health screenings and connect families with important wellness resources, including information about their CDPHP® dental benefits. These events are designed to promote whole-family health and help ensure children can learn, grow, and thrive. CDPHP® members can find in-network Delta Dental dentists at or by calling Delta Dental Customer Service at 1-800-542-9782. About All Smiles Welcome Delta Dental Insurance Company developed the All Smiles Welcome campaign to encourage CDPHP® members to take advantage of the dental benefits available through their plan. CDPHP® member plans include most regular and routine dental services at no additional cost. These dental benefits include preventive services like teeth cleanings, fluoride treatments, and molar sealants as well as restorative services to fix problems. To view the full list of covered services, visit Established in 1984, CDPHP® is a physician-founded, member-focused and community-based not-for-profit health plan that offers high-quality affordable health insurance plans to members in 36 counties throughout New York. CDPHP® is also on Facebook, X, LinkedIn, and Instagram.
Yahoo
an hour ago
- Yahoo
Miro Among the First to Attain AI Management Systems Standard ISO 42001
Certification demonstrates Miro's commitment to providing the highest standards of AI governance and empowering customers to innovate with Miro's AI tools with absolute confidence SAN FRANCISCO & AMSTERDAM, August 20, 2025--(BUSINESS WIRE)--Miro®, the AI-powered innovation workspace trusted by over 90 million users worldwide, today announced it has achieved ISO 42001 certification, the world's first AI management system standard. This milestone places Miro amongst the first enterprise SaaS (Software-as-a-Service) providers to achieve this certification, reinforcing the company's commitment to responsible AI development and governance. ISO/IEC 42001 is an international standard that specifies requirements for establishing, implementing, maintaining, and continually improving an Artificial Intelligence Management System (AIMS) within organizations. The standard helps organizations build trust and align with international best practices while addressing unique challenges AI poses, including ethical considerations, transparency and bias mitigation. "Achieving ISO 42001 certification represents a significant step in our AI journey and underscores our unwavering commitment to developing AI technologies responsibly," said Mark Strande, Chief Information Security Officer at Miro. "We are enabling responsible innovation at scale for users and empowering customers to adopt Miro's AI tools with confidence, knowing they are built on a common framework that considers ethics and transparency. It means a lot to be among the first of our peers to hit this milestone and enables Miro to continue to serve enterprise customers who require the highest levels of AI governance." ISO/IEC 42001 follows a structured plan-do-check-act (PDCA) approach and requires organizations to implement comprehensive controls across the AI lifecycle, including risk assessment, impact evaluation, data governance, system lifecycle management, and third-party supplier oversight. The standard's distinct controls apply a framework that allows organizations to demonstrate responsible AI management. The achievement builds on Miro's existing security and risk management certifications, including SOC 2 Type II and ISO 27001, creating a comprehensive framework for enterprise-grade trust, governance, and security. This milestone coincides with the general availability of Miro's Create with AI functionality, bringing powerful AI capabilities to the canvas like the ability to use teamwork and collaboration as the context for AI tooling generation across multiple formats. Together, these announcements signal Miro's readiness to support enterprises in deploying AI responsibly and confidently at scale. About Miro Miro is the Innovation Workspace that enables teams of any size to build the next big thing. The platform's intelligent canvas enables teams to quickly move from idea to outcome. Miro is co-headquartered in San Francisco and Amsterdam, and serves more than 90M users worldwide. Miro was founded in 2011 and currently has more than 1,600 employees in 14 hubs around the world. To learn more, please visit Miro and the Miro logo are trademarks or registered trademarks of RealtimeBoard, Inc., in the United States and/or other countries. Other product and company names mentioned herein may be the trademarks of their respective owners. View source version on Contacts press@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
